T. Rowe Price Investment Management, Inc. 13D and 13G filings for Apogee Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-07-08 11:30 am Sale | 2026-06-30 | 13G | APOGEE THERAPEUTICS INC APGE | T. Rowe Price Investment Management, Inc. | 772,969 1.300% | -9,518,251 (-92.49%) | Filing |
| 2026-04-08 3:26 pm Purchase | 2026-03-31 | 13G | APOGEE THERAPEUTICS INC APGE | T. Rowe Price Investment Management, Inc. | 10,291,220 16.800% | 4,077,393 (+65.62%) | Filing |
| 2026-03-06 12:57 pm Purchase | 2026-02-28 | 13G | APOGEE THERAPEUTICS INC APGE | T. Rowe Price Investment Management, Inc. | 6,213,827 11.300% | 6,213,827 (New Position) | Filing |